Stability of carboplatin in 5% glucose solution exposed to light

被引:5
作者
Torres, F
Girona, V
Puiol, M
Prat, J
deBolos, J
机构
[1] Unitat de Fisicoquímica, Facultat de Farmàcia, 08028 Barcelona, Avgda Joan XXIII s/n
关键词
kinetics; stability; carboplatin; degradation; photodegradation;
D O I
10.1016/0378-5173(95)04138-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The degradation of carboplatin (3.2 mg ml(-1) and 0.8 mg ml(-1)) in 5% glucose infusion solution at different experimental conditions was studied. It was observed that the degradation rate of carboplatin under illumination increases notably with respect to the rate obtained in the dark. The time course of carboplatin in solution follows a first-order kinetics with rate constants that depend on the incident light intensity and little with temperature. The time in which 10% of carboplatin has been degraded (t(90)) lies between 1 and 10 h depending on the experimental conditions. From the results obtained in the present work it is concluded that under clinical conditions, protection from light must be necessary.
引用
收藏
页码:275 / 277
页数:3
相关论文
共 6 条
[1]   STABILITY OF CISPLATIN, IPROPLATIN, CARBOPLATIN, AND TETRAPLATIN IN COMMONLY USED INTRAVENOUS SOLUTIONS [J].
CHEUNG, YW ;
CRADOCK, JC ;
VISHNUVAJJALA, BR ;
FLORA, KP .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1987, 44 (01) :124-130
[2]   ANALYTICAL METHODOLOGIES FOR THE QUANTITATION OF PLATINUM ANTICANCER DRUGS AND RELATED-COMPOUNDS IN BIOLOGICAL MEDIA [J].
DEWAAL, WAJ ;
MAESSEN, FJMJ ;
KRAAK, JC .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (01) :1-30
[3]   STABILITY OF CARBOPLATIN IN 5-PERCENT GLUCOSE SOLUTION IN GLASS, POLYETHYLENE AND POLYPROPYLENE CONTAINERS [J].
PRAT, J ;
PUJOL, M ;
GIRONA, V ;
MUNOZ, M ;
SOLE, LA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1994, 12 (01) :81-84
[4]  
PUJOL M, 1991, J CHEM RES, P258
[5]   STABILITY OF AQUEOUS CARBOPLATIN SOLUTIONS UNDER ILLUMINATION [J].
PUJOL, M ;
PART, J ;
TRILLAS, M ;
DOMENECH, X .
MONATSHEFTE FUR CHEMIE, 1993, 124 (11-12) :1077-1081
[6]  
VANECHO DA, 1984, CANCER TREAT REP, V68, P1103